Prostate Cancer Patients With Bone Metastasis Clinical Trial
Official title:
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
| NCT number | NCT00237159 |
| Other study ID # | CZOL446EDE07 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 4 |
| First received | October 9, 2005 |
| Last updated | March 21, 2011 |
| Start date | October 2002 |
| Verified date | March 2011 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Federal Institute for Drugs and Medical Devices |
| Study type | Interventional |
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
| Status | Completed |
| Enrollment | 284 |
| Est. completion date | |
| Est. primary completion date | December 2005 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility |
Inclusion criteria: - Signed informed consent - A histologically confirmed diagnosis of carcinoma of the prostate - Therapy with hormonal treatments (medical or surgical castration) - Patients must have objective evidence of metastatic disease to bone. - Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value - ECOG performance status of 0, 1 or 2 Exclusion criteria: - Bone pain which requires strong narcotic therapy with centrally acting analgesic agents. - More than 3 bisphosphonate applications in patients history. - Previous Radiation therapy to bone (including therapeutic radioisotopes such as strontium 89) within 3 months prior to Visit 2. - Abnormal renal function as evidenced by A calculated creatinine clearance < 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula: CrCl= [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x serum creatinine (mg/dL)] - Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or = 12.0 mg/dl (3.00 mmol/L) - Life expectancy < 6 months - Patients with evidence in the six months prior to randomization of severe cardiovascular disease (defined as uncontrolled congestive heart failure), hypertension refractory to treatment, or symptomatic coronary artery disease uncontrolled by treatment - Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to the date of randomization - Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. - Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants) Other protocol-defined inclusion and exclusion criteria may apply. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of skeletal complications | 3 months | No | |
| Secondary | Time to first skeletal complication | 3 months | No | |
| Secondary | Bone pain | 3 months | No | |
| Secondary | Patients´ satisfaction with treatment | 3 months | No | |
| Secondary | Bone turnover parameters | 3 months | No |